The two different effects of the potential neuroprotective compound minocycline on AMPA-type glutamate receptors

Pharmacology

Volumn 89, Issue 3-4, 2012, Pages 156-162

  Jin, Ling Jing ^a   Schlesinger, Friedrich ^b   Guan, Qiang ^a   Song, Yun Ping ^b   Nie, Zhi Yu ^a  

^a TONGJI UNIVERSITY   (China)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Amino 3 hydroxy 5 methyl 4 isoxazolepropionic acid receptor; Minocycline; Patch clamp technique

Indexed keywords

AMPA RECEPTOR; GLUTAMIC ACID; MINOCYCLINE;

AREA UNDER THE CURVE; ARTICLE; DOSE RESPONSE; DRUG EFFECT; HUMAN; HUMAN CELL; NEUROPROTECTION; PATCH CLAMP; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; STEADY STATE;

GLUTAMIC ACID; HEK293 CELLS; HUMANS; MINOCYCLINE; NEUROPROTECTIVE AGENTS; PATCH-CLAMP TECHNIQUES; RECEPTORS, AMPA;

EID: 84862790394     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000336773     Document Type: Article

References (30)

1. Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res 2009; 196: 168-179.
2. Plane JM, Shen Y, Pleasure DE, Deng W: Prospects for minocycline neuroprotection. Arch Neurol 2010; 67: 1442-1448.
3. Tikka TM, Vartiainen NE, Goldstein G, et al: Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain 2002; 125: 722-731. (Pubitemid 34279769)
4. Tikka T, Fiebich BL, Goldstein G, et al: Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 2001; 21: 2580-2588. (Pubitemid 32298200)
5. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W: Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002; 13: 1067-1070. (Pubitemid 34587742)
6. Zhu S, Stavrovskaya IG, Drozda M, et al: Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002; 417: 74-78. (Pubitemid 34498818)
7. Kriz J, Nguyen MD, Julien JP: Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002; 10: 268-278. (Pubitemid 35217580)
8. Gordon PH, Moore DH, Miller RG, et al: Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trial. Lancet Neurol 2007; 6: 1045-1053. (Pubitemid 350116691)
9. Manev H, Manev R: Interactions with GluR1 AMPA receptors could influence the therapeutic usefulness of minocycline in ALS. Amyotroph Lateral Scler 2009; 10: 416-417.
10. Carriedo SG, Yin HZ, Weiss JH: Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci 1996; 16: 4069-4079. (Pubitemid 26192403)
11. Van Den Bosch L, Vandenberghe W, Klaassen H, et al: Ca 2+ -permeable AMPA receptors and selective vulnerability of motor neurons. J Neurol Sci 2000; 180: 29-34.
12. Van Den Bosch L, Van Damme P, Vleminckx V, et al: An alpha- mercaptoacrylic acid derivative (PD150606) inhibits selective motor neuron death via inhibition of kainate-induced Ca 2+ influx and not via calpain inhibition. Neuropharmacology 2002; 42: 706-713. (Pubitemid 34457752)
13. Saroff D, Delfs J, Kuznetsov D, Geula C: Selective vulnerability of spinal cord motor neurons to non-NMDA toxicity. Neuroreport 2000; 11: 1117-1121. (Pubitemid 30235465)
14. Van Damme P, Dewil M, Robberecht W, Van Den Bosch L: Excitotoxicity and amyotrophic lateral sclerosis. Neurodegener Dis 2005; 2: 147-159. (Pubitemid 43827916)
15. Imbesi M, Uz T, Manev R, et al: Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors. Neurosci Lett 2008; 447: 134-137.
16. Schlesinger F, Tammena D, Krampfl K, Bufler J: Two mechanisms of action of the adamantane derivative IEM-1460 at human AMPA-type glutamate receptors. Br J Pharmacol 2005; 145: 656-663. (Pubitemid 41032637)
17. Krampfl K, Schlesinger F, Cordes AL, Bufler J: Molecular analysis of the interaction of the pyrazine derivatives RPR119990 and RPR117824 with human AMPA-type glutamate receptor channels. Neuropharmacology 2006; 50: 479-490. (Pubitemid 43209044)
18. Mansour M, Nagarajan N, Nehring RB, et al: Heteromeric AMPA receptors assemble with a preferred subunit stoichiometry and spatial arrangement. Neuron 2001; 32: 841-853. (Pubitemid 34024845)
19. Hamill OP, Marty A, Neher E, et al: Improved patch-clamp techniques for high-resolution current recording from cells and cellfree membrane patches. Pflügers Arch 1981; 391: 85-100. (Pubitemid 11012976)
20. Franke C, Hatt H, Dudel J: Liquid filament switch for ultra-fast exchanges of solutions at excised patches of synaptic membrane of crayfish muscle. Neurosci Lett 1987; 77: 199-204.
21. Jin LJ, Schlesinger F, Song YP, et al: The interaction of the neuroprotective compounds riluzole and phenobarbital with AMPA-type glutamate receptors: A patch-clamp study. Pharmacology 2010; 85: 54-62.
22. Krampfl K, Schlesinger F, Zorner A, et al: Control of kinetic properties of GluR2 flop AMPA-type channels: Impact of R/G nuclear editing. Eur J Neurosci 2002; 15: 51-62. (Pubitemid 35478009)
23. Bufler J, Franke C, Parnas H, Dudel J: Open channel block by physostigmine and procaine in embryonic-like nicotinic receptors of mouse muscle. Eur J Neurosci 1996; 8: 677-687. (Pubitemid 26114612)
24. Bufler J, Wilhelm R, Parnas H, et al: Open channel and competitive block of the embryonic form of the nicotinic receptor of mouse myotubes by (+)-tubocurarine. J Physiol 1996; 495: 83-95. (Pubitemid 26288455)
25. Staubli U, Rogers G, Lynch G: Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci USA 1994; 91: 777-781. (Pubitemid 24041485)
26. Sekiguchi M, Nishikawa K, Aoki S, Wada K: A desensitization-selective potentiator of AMPA-type glutamate receptors. Br J Pharmacol 2002; 136: 1033-1041.
27. Fucile S, Miledi R, Eusebi F: Effects of cyclothiazide on GluR1/AMPA receptors. Proc Natl Acad Sci USA 2006; 103: 2943-2947.
28. Pi R, Li W, Lee NT, et al: Minocycline prevents glutamate-induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways. J Neurochem 2004; 91: 1219-1230. (Pubitemid 39587460)
29. Diguet E, Fernagut PO, Wei X, et al: Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci 2004; 19: 3266-3276. (Pubitemid 38859544)
30. Yang L, Sugama S, Chirichigno JW, et al: Minocycline enhances MPTP toxicity to dopaminergic neurons. J Neurosci Res 2003; 74: 278-285. (Pubitemid 37193714)